Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Different risk profiles of biologic agents for new-onset psoriasis in patients with rheumatoid arthritis.

Baganz L, Listing J, Kekow J, Eisterhues C, Wassenberg S, Zink A, Strangfeld A.

Semin Arthritis Rheum. 2019 Jul 11. pii: S0049-0172(19)30351-8. doi: 10.1016/j.semarthrit.2019.07.004. [Epub ahead of print]

3.

Comparison of patient and physician perspectives in the management of rheumatoid arthritis: results from global physician- and patient-based surveys.

Gibofsky A, Galloway J, Kekow J, Zerbini C, de la Vega M, Lee G, Lee EY, Codreanu C, Koehn C, Steinberg K, Bananis E, de Leon DP, Maniccia A, Dikranian A; RA NarRAtive global advisory panel.

Health Qual Life Outcomes. 2018 Nov 9;16(1):211. doi: 10.1186/s12955-018-1035-3.

4.

Differential Effect of Cobalt and Chromium Ions as Well as CoCr Particles on the Expression of Osteogenic Markers and Osteoblast Function.

Drynda A, Drynda S, Kekow J, Lohmann CH, Bertrand J.

Int J Mol Sci. 2018 Oct 5;19(10). pii: E3034. doi: 10.3390/ijms19103034.

5.

The effects of cobalt and chromium ions on transforming growth factor-beta patterns and mineralization in human osteoblast-like MG63 and SaOs-2 cells.

Drynda S, Drynda A, Feuerstein B, Kekow J, Lohmann CH, Bertrand J.

J Biomed Mater Res A. 2018 Aug;106(8):2105-2115. doi: 10.1002/jbm.a.36409. Epub 2018 Apr 14.

PMID:
29577601
6.

Long-term effectiveness of tocilizumab in patients with rheumatoid arthritis, stratified by number of previous treatment failures with biologic agents: results from the German RABBIT cohort.

Baganz L, Richter A, Kekow J, Bussmann A, Krause A, Stille C, Listing J, Zink A, Strangfeld A.

Rheumatol Int. 2018 Apr;38(4):579-587. doi: 10.1007/s00296-017-3870-7. Epub 2017 Nov 16.

7.

[Biosimilars in Rheumatologie: a New Challenge?]

Kekow J.

Dtsch Med Wochenschr. 2017 Apr;142(7):521-524. doi: 10.1055/s-0042-121455. Epub 2017 Apr 7. German. No abstract available.

PMID:
28388749
8.

Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis.

Horneff G, Peitz J, Kekow J, Foell D.

Scand J Rheumatol. 2017 Nov;46(6):500-501. doi: 10.1080/03009742.2017.1288827. Epub 2017 Mar 7. No abstract available.

PMID:
28266235
9.

Impact of disease activity and treatment of comorbidities on the risk of myocardial infarction in rheumatoid arthritis.

Meissner Y, Zink A, Kekow J, Rockwitz K, Liebhaber A, Zinke S, Gerhold K, Richter A, Listing J, Strangfeld A.

Arthritis Res Ther. 2016 Aug 5;18(1):183. doi: 10.1186/s13075-016-1077-z.

10.

Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.

Schotte H, Schmidt H, Gaubitz M, Drynda S, Kekow J, Willeke P, Schlüter B.

Clin Rheumatol. 2015 Dec;34(12):2021-8. doi: 10.1007/s10067-015-3107-7. Epub 2015 Nov 3.

PMID:
26526676
11.

Putative IL-10 Low Producer Genotypes Are Associated with a Favourable Etanercept Response in Patients with Rheumatoid Arthritis.

Schotte H, Schlüter B, Schmidt H, Gaubitz M, Drynda S, Kekow J, Willeke P.

PLoS One. 2015 Jun 24;10(6):e0130907. doi: 10.1371/journal.pone.0130907. eCollection 2015.

12.

[Inpatient rheumatology treatment in Germany].

Kekow J.

Z Rheumatol. 2014 Mar;73(2):135-8. doi: 10.1007/s00393-013-1261-3. German.

PMID:
24659149
13.

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab.

Listing J, Kekow J, Manger B, Burmester GR, Pattloch D, Zink A, Strangfeld A.

Ann Rheum Dis. 2015 Feb;74(2):415-21. doi: 10.1136/annrheumdis-2013-204021. Epub 2013 Nov 29.

14.

Long-term persistence and effects of fetal microchimerisms on disease onset and status in a cohort of women with rheumatoid arthritis and systemic lupus erythematosus.

Kekow M, Barleben M, Drynda S, Jakubiczka S, Kekow J, Brune T.

BMC Musculoskelet Disord. 2013 Nov 18;14:325. doi: 10.1186/1471-2474-14-325.

15.

Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure.

Kekow J, Mueller-Ladner U, Schulze-Koops H.

Biologics. 2012;6:191-9. doi: 10.2147/BTT.S32244. Epub 2012 Jul 2.

16.

Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.

Moots RJ, Haraoui B, Matucci-Cerinic M, van Riel PL, Kekow J, Schaeverbeke T, Davis A, Tedeschi MA, Freundlich B, Chang DJ, Singh A.

Clin Exp Rheumatol. 2011 Jan-Feb;29(1):26-34. Epub 2011 Feb 23.

PMID:
21345289
17.

Comparative effects of teriparatide and strontium ranelate in the periosteum of iliac crest biopsies in postmenopausal women with osteoporosis.

Ma YL, Marin F, Stepan J, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Martínez G, Malouf J, Zeng QQ, Wan X, Recker RR.

Bone. 2011 May 1;48(5):972-8. doi: 10.1016/j.bone.2011.01.012. Epub 2011 Jan 22.

PMID:
21262402
18.

[Diagnostic spectrum, treatment indication and symptom duration in initial referrals to the rheumatologist].

Westhoff G, Edelmann E, Kekow J, Zink A.

Z Rheumatol. 2010 Dec;69(10):910-8. doi: 10.1007/s00393-010-0715-0. German.

PMID:
21088969
19.

Improvements in patient-reported outcomes, symptoms of depression and anxiety, and their association with clinical remission among patients with moderate-to-severe active early rheumatoid arthritis.

Kekow J, Moots R, Khandker R, Melin J, Freundlich B, Singh A.

Rheumatology (Oxford). 2011 Feb;50(2):401-9. doi: 10.1093/rheumatology/keq327. Epub 2010 Nov 8.

PMID:
21059675
20.

Rheumatoid pneumoconiosis (Caplan's syndrome).

Schreiber J, Koschel D, Kekow J, Waldburg N, Goette A, Merget R.

Eur J Intern Med. 2010 Jun;21(3):168-72. doi: 10.1016/j.ejim.2010.02.004. Epub 2010 Mar 2. Review.

PMID:
20493416
21.

Genetic variations in genes encoding RANK, RANKL, and OPG in rheumatoid arthritis: a case-control study.

Assmann G, Koenig J, Pfreundschuh M, Epplen JT, Kekow J, Roemer K, Wieczorek S.

J Rheumatol. 2010 May;37(5):900-4. doi: 10.3899/jrheum.091110. Epub 2010 Mar 15.

PMID:
20231205
22.

["TRECID", TNFalpha related chronic inflammatory diseases - a new multiple diseases bridging concept].

Müller-Ladner U, Alten R, Heiligenhaus A, Kekow J, Koletzko S, Mrowietz U, Ochsenkühn T, Radke M, Reich K, Rudwaleit M, Schreiber S.

Dtsch Med Wochenschr. 2009 Oct;134(42):2132-6. doi: 10.1055/s-0029-1242011. Epub 2009 Oct 6. Review. German.

PMID:
19809965
23.

[Bone densitometry in inflammatory rheumatic diseases : Characteristics of the measurement site and disease-specific factors].

Franck H; Kommission Osteologie der Deutschen Gesellschaft für Rheumatologie, Braun J, Buttgereit F, Demary W, Hein G, Kekow J, Schett G, Kern PM.

Z Rheumatol. 2009 Dec;68(10):845-50. doi: 10.1007/s00393-009-0502-y. Review. German.

PMID:
19714343
24.

MS characterization of apheresis samples from rheumatoid arthritis patients for the improvement of immunoadsorption therapy - a pilot study.

Kienbaum M, Koy C, Montgomery HV, Drynda S, Lorenz P, Illges H, Tanaka K, Kekow J, Guthke R, Thiesen HJ, Glocker MO.

Proteomics Clin Appl. 2009 Jul;3(7):797-809. doi: 10.1002/prca.200800232.

PMID:
21136988
25.

Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Recker RR, Marin F, Ish-Shalom S, Möricke R, Hawkins F, Kapetanos G, de la Peña MP, Kekow J, Farrerons J, Sanz B, Oertel H, Stepan J.

J Bone Miner Res. 2009 Aug;24(8):1358-68. doi: 10.1359/jbmr.090315.

26.

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial.

Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, Pedersen R, Robertson D, Freundlich B, Sato R.

Ann Rheum Dis. 2010 Jan;69(1):222-5. doi: 10.1136/ard.2008.102509. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19293160
27.

[Possibilities and limitations of genomic analyses in rheumatoid arthritis].

Drynda S, Kekow J.

Z Rheumatol. 2009 Feb;68(1):65-8. doi: 10.1007/s00393-008-0408-0. Review. German.

PMID:
19145443
28.

Comparative effectiveness of tumour necrosis factor alpha inhibitors in combination with either methotrexate or leflunomide.

Strangfeld A, Hierse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R, Listing J, Zink A.

Ann Rheum Dis. 2009 Dec;68(12):1856-62. doi: 10.1136/ard.2008.098467. Epub 2009 Jan 6.

PMID:
19126559
29.

Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept.

Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ.

Arthritis Res Ther. 2008;10(3):R50. doi: 10.1186/ar2419. Epub 2008 May 2.

30.

Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?

Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.

Arthritis Rheum. 2008 Mar;58(3):667-77. doi: 10.1002/art.23281.

31.

Mass spectrometric and peptide chip epitope analysis on the RA33 autoantigen with sera from rheumatoid arthritis patients.

El-Kased RF, Koy C, Lorenz P, Drynda S, Guthke R, Qian Z, Koczan D, Li Y, Kekow J, Thiesen HJ, Glocker MO.

Eur J Mass Spectrom (Chichester). 2010;16(3):443-51. doi: 10.1255/ejms.1046.

PMID:
20530829
32.

[Current status and perspectives of ambulatory rheumatologic health care in Germany : economic structural conditions and motivation of rheumatologists].

Mittendorf T, Edelmann E, Kekow J, von Hinüber U, Müller-Brodmann W, Graf von der Schulenburg JM.

Z Rheumatol. 2007 Nov;66(7):611-20. German.

PMID:
17885760
33.

[Current status of ambulatory rheumatologic health care in Germany. Structure of health care and range of services].

Mittendorf T, Edelmann E, Kekow J, von Hinüber U, Müller-Brodmann W, Graf von der Schulenburg JM.

Z Rheumatol. 2007 Oct;66(6):525-32. German.

PMID:
17851671
34.

Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register.

Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, Demary W, Burmester GR, Zink A.

Arthritis Res Ther. 2006;8(3):R66. Epub 2006 Apr 5.

35.

Rheumatoid arthritis, a complex multifactorial disease: on the way toward individualized medicine.

Glocker MO, Guthke R, Kekow J, Thiesen HJ.

Med Res Rev. 2006 Jan;26(1):63-87. Review.

PMID:
16283676
36.

Infections in patients with rheumatoid arthritis treated with biologic agents.

Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, Gromnica-Ihle E, Antoni C, Herzer P, Kekow J, Schneider M, Zink A.

Arthritis Rheum. 2005 Nov;52(11):3403-12.

37.

Gene transfer of tissue inhibitor of metalloproteinases-3 reverses the inhibitory effects of TNF-alpha on Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts.

Drynda A, Quax PH, Neumann M, van der Laan WH, Pap G, Drynda S, Meinecke I, Kekow J, Neumann W, Huizinga TW, Naumann M, König W, Pap T.

J Immunol. 2005 May 15;174(10):6524-31.

38.

Treatment continuation in patients receiving biological agents or conventional DMARD therapy.

Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, von Hinueber U, Gromnica-Ihle E, Wassenberg S, Antoni C, Herzer P, Kekow J, Schneider M, Rau R.

Ann Rheum Dis. 2005 Sep;64(9):1274-9. Epub 2005 Feb 11.

39.

Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis.

Schotte H, Schlüter B, Drynda S, Willeke P, Tidow N, Assmann G, Domschke W, Kekow J, Gaubitz M.

Ann Rheum Dis. 2005 Apr;64(4):575-81. Epub 2004 Sep 2.

40.

Proteome analysis reveals disease-associated marker proteins to differentiate RA patients from other inflammatory joint diseases with the potential to monitor anti-TNFalpha therapy.

Drynda S, Ringel B, Kekow M, Kühne C, Drynda A, Glocker MO, Thiesen HJ, Kekow J.

Pathol Res Pract. 2004;200(2):165-71.

PMID:
15237925
41.

[Specialties in therapy of osteoporosis in inflammatory joint disease].

Franck H, Braun J, Buttgereit F, Dreher R, Hein G, Kekow J.

Z Rheumatol. 2004 Jun;63(3):223-9. Review. German.

PMID:
15224226
42.

Increased blood plasma concentrations of TGF-beta isoforms after treatment with intravenous immunoglobulins (i.v.IG) in patients with multiple sclerosis.

Reinhold D, Perlov E, Schrecke K, Kekow J, Brune T, Sailer M.

J Neuroimmunol. 2004 Jul;152(1-2):191-4.

PMID:
15223252
43.

Complex genetic predisposition in adult and juvenile rheumatoid arthritis.

Miterski B, Drynda S, Böschow G, Klein W, Oppermann J, Kekow J, Epplen JT.

BMC Genet. 2004 Feb 4;5:2.

44.

[Diagnosis and therapy monitoring applying methods of molecular medicine].

Kekow J, Drynda S.

Z Rheumatol. 2002;61 Suppl 2:II/6-9. Review. German.

PMID:
12491115
45.

Mass spectrometric proteome analyses of synovial fluids and plasmas from patients suffering from rheumatoid arthritis and comparison to reactive arthritis or osteoarthritis.

Sinz A, Bantscheff M, Mikkat S, Ringel B, Drynda S, Kekow J, Thiesen HJ, Glocker MO.

Electrophoresis. 2002 Sep;23(19):3445-56.

PMID:
12373775
46.

Bone substitutes as carriers for transforming growth factor-beta(1) (TGF-beta(1)).

Gille J, Dorn B, Kekow J, Bruns J, Behrens P.

Int Orthop. 2002;26(4):203-6. Epub 2002 Apr 23.

47.

Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept.

Kekow J, Welte T, Kellner U, Pap T.

Arthritis Rheum. 2002 Mar;46(3):843-4. No abstract available.

49.

WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis.

Emery P, Reginster JY, Appelboom T, Breedveld FC, Edelmann E, Kekow J, Malaise M, Mola EM, Montecucco C, Sanda M, Sany J, Scott DL, Serni U, Seydoux G.

Rheumatology (Oxford). 2001 Jun;40(6):699-702.

PMID:
11426031
50.

Capsule impedes adhesion to and invasion of epithelial cells by Klebsiella pneumoniae.

Sahly H, Podschun R, Oelschlaeger TA, Greiwe M, Parolis H, Hasty D, Kekow J, Ullmann U, Ofek I, Sela S.

Infect Immun. 2000 Dec;68(12):6744-9.

Supplemental Content

Support Center